Eli Lilly Drug Retatrutide Shows Weight Loss in Type 2 Diabetes Trial

Why it matters locally: With a significant portion of Georgia's population affected by Type 2 diabetes, the potential availability of a new treatment like retatrutide could have a notable impact on healthcare and public health efforts across the state.

Eli Lilly's experimental drug retatrutide led to significant weight loss among individuals with Type 2 diabetes. Participants in a late-stage clinical trial lost up to 60 pounds, which represented approximately 23% of their body weight. Researchers published the findings from the study in The Lancet on Tuesday. The results detail the effects of retatrutide, a GLP-1 receptor agonist, in individuals diagnosed with Type 2 diabetes.